Trials / Active Not Recruiting
Active Not RecruitingNCT06357806
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | 100mg/10ml/1bottle |
| DRUG | Peg-IFNα-2b | 180ug/0.5ml/1bottle |
| DRUG | NAs | tablets |
Timeline
- Start date
- 2024-05-17
- Primary completion
- 2026-10-08
- Completion
- 2026-10-08
- First posted
- 2024-04-10
- Last updated
- 2026-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06357806. Inclusion in this directory is not an endorsement.